Ensign Peak Advisors
MLYS icon

Ensign Peak Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Ensign Peak Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.04M Hold
112,190
– – 0.01% 630
2025
Q4 		$4.07M Buy
112,190
+4,550
+4% +$182K 0.01% 558
2025
Q3 		$4.08M Hold
107,640
– – 0.01% 637
2025
Q2 		$1.46M Buy
107,640
+70,147
+187% +$1.02M ﹤0.01% 1036
2025
Q1 		$595K Buy
+37,493
New +$431K ﹤0.01% 1502
2024
Q4 		– Sell
-125,000
Closed -$1.51M – 1719
2024
Q3 		$1.51M Hold
125,000
– – ﹤0.01% 1084
2024
Q2 		$1.46M Hold
125,000
– – ﹤0.01% 1052
2024
Q1 		$1.61M Hold
125,000
– – ﹤0.01% 1020
2023
Q4 		$1.07M Hold
125,000
– – ﹤0.01% 1319
2023
Q3 		$1.19M Hold
125,000
– – ﹤0.01% 1061
2023
Q2 		$2.13M Hold
125,000
– – ﹤0.01% 854
2023
Q1 		$1.96M Buy
+125,000
New +$2.1M ﹤0.01% 863

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Ensign Peak Advisors's MLYS Position: Q1 2026 in Review

Ensign Peak Advisors held its Mineralys Therapeutics (MLYS) position steady in Q1 2026 at 112,190 shares worth $3.04M. The position accounts for 0.01% of the portfolio, ranked #630.

Ensign Peak Advisors first reported a position in MLYS in Q1 2023 and has held it in 12 quarters since. The position peaked at $4.08M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Ensign Peak Advisors held 112,190 shares of Mineralys Therapeutics worth $3.04M as of Q1 2026.
  • Ensign Peak Advisors left its Mineralys Therapeutics share count unchanged in Q1 2026.
  • Mineralys Therapeutics made up 0.01% of Ensign Peak Advisors's portfolio in Q1 2026, its #630 holding.
  • Ensign Peak Advisors first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • Ensign Peak Advisors's Mineralys Therapeutics position peaked at $4.08M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.